Umbilical Cord Mesenchymal Stem Cell Secretome Improves Clinical Outcomes and Changes Biomarkers in Knee Osteoarthritis
Journal of Clinical Medicine · 16.11.2023 · 12 (22) · 7138
DOI: 10.3390/jcm12227138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.11.2023. Verfasst von Radiyati Umi Partan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Division of Rheumatology, Faculty of Medicine, Sriwijaya University-Dr. Mohammad Hoesin Hospital, Palembang 30126, Indo…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Mohammad Hoesin Hospital.
Abstract (Originalsprache)
(1)
Background
The current treatment for osteoarthritis is ineffective due to its focus on pain relief and lack of cartilage repair. Viscosupplementation such as hyaluronic acid improves symptoms but remains unnoticed for several months. Researchers are exploring cell-based therapies such as mesenchymal stem cells secretome and mesenchymal stem cells, which can repair cartilage damage. The objective of the research is to evaluate and compare the effectiveness of the secretome derived from umbilical cord mesenchymal stem cells (UC-MSCs) with hyaluronic acid (HA). (2)
Methods
An open-label clinical trial involving 30 knee osteoarthritis patients divided into two groups received UC-MSC secretome and hyaluronic acid doses. The study assessed clinical outcomes using VAS and WOMAC and measured MMP-3 and TGF-β1 levels before and after treatment. (3)
Results
A study of 30 subjects found that the UC-MSC secretome group showed a decrease in pain in the OA knee compared to the HA group. The therapy was most effective after the third injection, and the group showed a decrease in the MMP-3 ratio and an increase in TGF-β1 compared to the hyaluronic acid group. (4)
Conclusions
UC-MSC secretome intra-articular injections showed superior clinical improvement, biomarker changes, and no side effects compared to hyaluronic acid over a 5-week interval.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Department, Division of Rheumatology, Faculty of Medicine, Sriwijaya University-Dr. Mohammad Hoesin Hospital, Palembang 30126, Indonesia.
- Stem Cell and Regenerative Therapies, From Bench to Market Program, Faculty of Life Science & Medicine, King's College London, London WC2R 2LS, UK.
- Department of Pharmacology, Faculty of Medicine, Sriwijaya University, Palembang 30126, Indonesia.
- Internal Medicine Department, Division of Allergy & Immunology, Faculty of Medicine, Sriwijaya University-Dr. Mohammad Hoesin Hospital, Palembang 30126, Indonesia.
ORCID-Profile: Radiyati Umi Partan, Khoirun Mukhsinin Putra
Förderung
- Dr. Mohammad Hoesin Hospital
Zitieren
APA
Partan, R. U., Putra, K. M., Kusuma, N. F., Darma, S., Reagan, M., Muthia, P., Radiandina, A. S., Saleh, M. I., & Salim, E. M. (2023). Umbilical Cord Mesenchymal Stem Cell Secretome Improves Clinical Outcomes and Changes Biomarkers in Knee Osteoarthritis. Journal of Clinical Medicine, 12(22), 7138. https://doi.org/10.3390/jcm12227138
Vancouver
Partan RU, Putra KM, Kusuma NF, Darma S, Reagan M, Muthia P, et al. Umbilical Cord Mesenchymal Stem Cell Secretome Improves Clinical Outcomes and Changes Biomarkers in Knee Osteoarthritis. Journal of Clinical Medicine. 2023;12(22):7138. doi:10.3390/jcm12227138
BibTeX
@article{Partan2023,
author = {Partan, Radiyati Umi and Putra, Khoirun Mukhsinin and Kusuma, Narisa Felinka and Darma, Surya and Reagan, Muhammad and Muthia, Putri and Radiandina, Afifah Salshabila and Saleh, Mgs Irsan and Salim, Eddy Mart},
title = {Umbilical Cord Mesenchymal Stem Cell Secretome Improves Clinical Outcomes and Changes Biomarkers in Knee Osteoarthritis},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {22},
pages = {7138},
doi = {10.3390/jcm12227138}
}
EUVIMED